Skip to main content

Table 1 Summary of studies that evaluated the role of PPTR

From: Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen

First author and reference number Period of patient involvement Chemotherapy regimen PPTR No. of patients Median OS (months) P
Seo [4] 2001–2008 Oxaliplatin, irinotecan, and 5-FU Yes 144 22 0.076
No 83 14
Sabine [16] 2003–2004 Irinotecan, oxaliplatin, and capecitabine Yes 258 16.7 <0.001
No 141 11.4
Sabine [16] 2005–2006 Oxaliplatin and capecitabine Yes 289 20.7 <0.001
No 159 13.4
Leyo [17] 1996–1999 Unknown Yes 127 16 <0.001
No 103 9
Ferrand [18] 1997–2001 5-FU + CF, 5-FU, or raltitrexed Yes 156 16.3 <0.001
No 60 9.6
Mehdi [19] 1998–2007 FOLFOX, FOLFIRI, XELOX, or 5-FU Yes 85 30.7 0.031
No 123 21.9
Tebutt [20] 1990–1999 5-FU, raltitrexed, capecitabine, or uracil tegafur Yes 280 14 0.080
No 82 8.2
Martyn [21] 1999–2006 Unknown Yes 45 11 0.206
No 52 7
  1. PPTR palliative primary tumor resection, OS overall survival, 5-FU 5-fluorouracil, CF cisplatin and 5-fluorouracil, FOLFOX folinic acid 5-fluorouracil and oxaliplatin, FOLFIRI folinic acid, 5-fluorouracil, and irinotecan, XELOX xeloda and oxaliplatin